beta

ETTX

Entasis Therapeutics Holdings Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).

Market Cap: 105 Million

Primary Exchange: NASDAQ

Website: www.entasistx.com

Shares Outstanding: 47.9 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.47096490584059997

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 1129 trading days

From: 2018-09-28 To: 2022-07-08

Lowest Point:

Key events next week - healthcare

via: SeekingAlpha at 2019-06-13 03:28:10:000

Noteworthy events during the week of June 16 - 22 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Merck & Co., Inc., IQVIA Holdings Inc., Healthcare stocks news, , Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud